Atezolizumab 1200 mg/20 mL Suppliers & Bulk Manufacturers
Available Forms: Intravenous infusion
Available Strengths: 1200 mg/20 mL
Reference Brands: Tecentriq® (EU & US)
Category: Oncology Cancer Care
Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing.
Product Description:
Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.
Atezolizumab — third party manufacturing & bulk supply
Atezolizumab 1200 mg/20 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Atezolizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Atezolizumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Atezolizumab is used to treat several types of cancer, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, triple-negative breast cancer, and urothelial carcinoma. It works by blocking the PD-L1 protein on tumor cells, helping the immune system detect and destroy cancer cells more effectively.
Atezolizumab is a humanized monoclonal antibody created using recombinant DNA technology. It is produced from genetically engineered Chinese hamster ovary (CHO) cells that express an antibody specifically targeting PD-L1, a protein found on tumor and immune cells.
The trade name of Atezolizumab is Tecentriq.
Atezolizumab is developed and manufactured by Genentech, Inc., which is a member of the Roche Group, a global leader in cancer immunotherapy.
The generic name of the product is Atezolizumab.
The brand name of the product is Tecentriq.
Atezolizumab (Tecentriq) is manufactured by Genentech, Inc. in the United States, and additional manufacturing and packaging for international supply are handled at Roche production facilities in Europe and other regions.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
